Skip to main content

Overview

Genetic epidemiology of prostate cancer

Hanna Rennert, Ph.D., F.A.C.M.G. is Assistant Professor of Pathology and Laboratory Medicine at Weill Medical College of Cornell University, and Director of the Molecular Pathology Laboratory at the New York Presbyterian Hospital – Weill Cornell Medical Center. She received her Ph.D. in Biochemistry from the Technion-Israel Institute of Technology Medical School. Following postdoctoral training at the University of Pennsylvania, Dr. Rennert served in oversight roles within the Molecular Pathology Laboratory in the Department of Pathology and Laboratory Medicine. From 2000 until 2002, she directed a Microarray Research and Development Laboratory at Tel-Aviv Sourasky Medical Center. Dr. Rennert rejoined the University of Pennsylvania School of Medicine in 2002 as a Senior Molecular Genetics Scientist and adjunct faculty in Molecular Pathology. She is certified by the American Board of Medical Genetics in Clinical Molecular Genetics, and is obtaining a certificate in Clinical Epidemiology from the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania. Dr. Rennert directed the Molecular Diagnosis and Genotyping Facility within the Pathology Department until July 2005 when she came to Weill Cornell Medical College.

Highlights

  1. 1
    The Journal of molecular diagnostics : JMD · 2023
    PMID: 37474002DOISenior author6 citations
  2. 2
    Diagnostic microbiology and infectious disease · 2022
    PMID: 36122486PMCID: PMC9392658DOISenior author3 citations
  3. 3
    The Journal of molecular diagnostics : JMD · 2020
    PMID: 33285285PMCID: PMC7718583DOISenior author3 citations

Publications

106 publications

Funding

5 grants

Active

1 grant
  • Co-I
    QSM for detection of hemorrhaging cysts and risk stratification in ADPKD
    National Institute of Diabetes and Digestive and Kidney Diseases · 2025–2029
    R01DK139336-01A1
Completed grants (4)
  • PI
    Master Services Agreement with Vertex
    Vertex Pharmaceuticals · 2020–2025Contract
    VPI 204791-01
  • Co-I
    Biomolecular Markers for Safe Minimization of Immunosuppression
    National Institute of Allergy and Infectious Diseases · 2014–2022· 2 renewals
    R37AI051652-15S1
  • PI
    Sponsored Research Agreement Vertex and Dr. Hanna Rennert (WCM)
    Vertex Pharmaceuticals · 2019–2020Contract
    SRA 192028-01
  • PI
    SRA Amendment No. 1 (changing payment term deadlines)
    Vela Diagnostics · 2018–2019Contract
    SRA 190021-01

News mentions